ADE (chemotherapy)

Medical intervention

ADE

Specialty| Oncology

[edit on Wikidata]

ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy.

ADE regimen consists of three drugs:

1. Ara-C (cytarabine) \- an antimetabolite;
2. Daunorubicin \- an anthracycline antibiotic that is able to intercalate DNA and thus disrupt the cell division cycle, preventing mitosis;
3. Etoposide \- a topoisomerase inhibitor.[1]

## Dosing regimen

[edit]

Drug | Dose | Mode | Days

|
|
|

Ara-C (cytarabine) | 200 mg/m2 | IV push every 12 hours in 2 divided doses (100 mg/m2 each) | Days 1-10
Daunorubicin | 50 mg/m2 | IV slow push | Days 1, 3 and 5
Etoposide | 100 mg/m2 | IV infusion over 1 hour | Days 1-5

## References

[edit]

1. ^ "Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial". Archived from the original on 2015-09-23. Retrieved 2014-09-15.